HCV (hepatitis C virus) poly-epitope peptide vaccine and application thereof

Abstract

The invention discloses an HCV (hepatitis C virus) poly-epitope peptide vaccine and application thereof. The HCV poly-epitope peptide vaccine comprises the following poly-epitope polypeptides: poly-epitope polypeptide of which the amino acid residue sequence is disclosed as SEQ.ID.NO.1, or poly-epitope polypeptide of which the amino acid residue sequence is disclosed as SEQ.ID.NO.2. The polypeptide VAL-44 HCV can induce the specific T cell immune response, including CD4 cells and CD8 cells; and the T cells can quickly generate IFN-gamma and IL-2 after being subjected to specific antigenic stimulation. The HCV polypeptide vaccine can stimulate 3 of 10 chronic HCV infected persons PBMC to secrete IFN-gamma. The HCV poly-epitope polypeptide can be an ideal HCV preventive / curative candidate vaccine.

Description

technical field [0001] The invention belongs to the technical field of HCV vaccines, and relates to an HCV multi-epitope peptide vaccine and its application. Background technique [0002] Hepatitis C virus (HCV), a single-stranded positive-sense hepatotropic RNA virus of the genus Flavivirus, is the main pathogen that causes chronic liver disease. There are about 170 million infected people in the world, and the number of cases is 3 million per year. increment. Chronic HCV infection is directly related to liver cirrhosis and liver cancer, seriously affecting the quality of life of patients. Due to the high cost and unsatisfactory efficacy of standard HCV treatment regimens, most HCV-infected patients in developing countries cannot afford it. Therefore, the development of HCV vaccine has become one of the most effective strategies to reduce the incidence of liver cirrhosis and liver cancer caused by HCV. [0003] The HCV genome encodes core protein C, envelope proteins E1,...

AI Technical Summary

Problems solved by technology

Although the T cell response of chronic HCV patients is polyclonal and multispecific, its intensity is far less than that of acute patients, and the relatively weak anti-HCV immune response makes it difficult to clear the virus

At the same time, a large number of HCV-specific CD8 + The level of interferon-gamma secreted by T cells is suppressed, therefore, during chronic HCV infection, CD8 + T cell dysfunction is the main reason for the inability of the immune system to control HCV replication, leading to chronic disease

Images